Thoracic Malignancies
Conditions
Brief summary
This phase II study is to evaluate the safety and efficacy of CT-based adaptive radiation therapy followed by adjuvant anti-PD-1 antibody immunotherapy in treating patients with different types and stages of thoracic malignancies. (CARTAI)
Detailed description
PRIMARY OBJECTIVES: I. To evaluate the safety and toxicity of anti-programmed cell death 1 (PD-1) inhibition consolidation therapy after radiation therapy for multiple thoracic malignancies. SECONDARY OBJECTIVES: I. To assess the efficacy of adjuvant anti-PD-1 antibody immunotherapy after radiotherapy. II. To understand the dynamics and interactions of IDO with others immune pathway biomarkers. III. To evaluate whether IDO immune status could predict the treatment outcomes of radiation and immune combined therapy.
Interventions
DRUGIBI308
A humanized anti-PD-1 monoclonal antibody
Sponsors
Taizhou Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Signed inform consent form 2. Age \>= 18 years and \<= 75 years 3. Histologically or cytologically confirmed advanced/metastatic thoracic malignancies 4. Patients must receive adaptive radiation therapy within 45 days before the first dose of trial treatment 5. Eastern Cooperative Oncology Group performance status of 0 or 1 6. Life expectancy \>= 8 weeks 7. Adequate hematologic and end organ function
Exclusion criteria
1. Prior exposure to any immune checkpoint inhibitors including but not limited to anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibodies. 2. Prior exposure to any other thoracic radiation therapy before this time radiation therapy. 3. Prior exposure to steroid therapy or any other form of immunosuppressive therapy within 14 days before the first dose of trial treatment 4. No active second cancers 5. Active or prior autoimmune disease or immunodeficiency. 6. Active infections including but not limited to hepatitis B, C ,and HIV. 7. Significant cardiovascular disease 8. Active or untreated central nervous system (CNS) metastases 9. Any unresolved toxicity CTCAE \>= Grade 3 from the prior radiation therapy. 10. Known hypersensitivity to humanized antibodies or fusion proteins or any of study drug excipients. 11. Known psychiatric or physical impairments that would interfere with cooperation with the protocol of this trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AEs and SAEs at 6 months | 6 months | Number of participants with adverse events and serious adverse events at 6 months will be measured. \[CTCAE v4.03\] |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ORR | Estimated to be up to 3 years | Objective response rate is the percentage of patients with at least once occurrence of PR or CR \[RECIST v1.1\] |
| DoR | Estimated to be up to 3 years | Duration of response is the time interval from first occurrence of PR or CR until PD or death \[RECIST v1.1\] |
| AEs | Estimated to be up to 3 years | Number of patients with acute and chronic adverse events will be measured \[CTCAE v4.03\] |
| PFS | Estimated to be up to 3 years | Progression-Free-Survival is the time interval from the start of treatment until disease progression or death by any cause \[RECIST v1.1\] |
| OS | Estimated to be up to 3 years | Overall Survival is the time interval from the start of treatment to death from any cause. |
Countries
China
Contacts
Primary ContactHaihua Yang, MD
Backup ContactYinnan Meng, MD
Outcome results
None listed